Evidence status: DOCUMENTED 2022 LEGISLATIVE REFORM. Minnesota substantially rewrote its intractable-pain statute in Chapter 98 of the 2022 Session Laws.
Agreement requirement created in current form
The 2022 law added the current patient-provider agreement subdivision requiring mutual agreement, signatures, medical-record retention, annual review, updates after treatment-plan changes, and a patient copy.
Anti-cutoff protection
The same legislation added the rule that, absent clear evidence of drug diversion, agreement nonadherence cannot be the sole reason to stop scheduled-drug treatment. Difficulty adhering to the agreement must trigger evaluation for other conditions and appropriate treatment adjustment.
Anti-forced-taper protection
The 2022 reform also prohibited tapering stable, compliant intractable-pain patients solely to meet predetermined MME recommendations or thresholds and barred threshold-only refusal by pharmacists, health plans, or PBMs.
Expanded prescriber scope
The law expanded the intractable-pain framework beyond physicians to include advanced practice registered nurses and physician assistants.
Broader intractable-pain definition
The revised statute expressly recognized conditions including cancer, sickle cell disease, noncancer pain, rare/orphan diseases, severe injuries, and palliative/hospice conditions.
Why the 2022 history matters
Minnesota paired a mandatory agreement with unusually explicit protections against mechanical contract enforcement and dose-threshold tapering. Both sides of that reform belong in the public record.
Primary source
Reviewed: October 5, 2026.